GKSL Q1 FY27 Un-Audited Financial Results Reviewed
Gujarat Kidney And Superspeciality Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The results have been reviewed by independent auditors and taken on record by the Board of Directors.
This is a standard quarterly financial results announcement and review. The provided text does not contain specific financial figures or forward-looking statements that would significantly impact investor decisions.
The announcement is a routine disclosure of reviewed financial results for the quarter, with no specific positive or negative financial performance metrics provided in the excerpt. The auditor's report confirms no material misstatements were found.
Gujarat Kidney And Superspeciality Limited (GKSL) has announced the outcome of its Board Meeting concerning the unaudited financial results for the first quarter ended June 30, 2026. The company's Board of Directors has taken on record the standalone and consolidated financial results for the said quarter.
The financial statements, prepared in accordance with Indian Accounting Standard 34 (Interim Financial Reporting), have been reviewed by the independent auditor, Y. M. Shah & Co., Chartered Accountants. The review was conducted as per the Standard on Review Engagements (SRE) 2014, which involves inquiries of company personnel and analytical procedures to ensure that the statements are free of material misstatement.
The auditor's report states that nothing has come to their attention to suggest that the accompanying standalone and consolidated financial statements, prepared in accordance with applicable Indian Accounting Standards, do not disclose the information required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, or that they contain any material misstatement. The financial results for the corresponding quarter ended June 30, 2025, were also subject to a limited review or audit.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.